About
DeepCure is a cutting-edge AI-driven therapeutics company headquartered in Boston, MA, that is reimagining small molecule drug discovery for immune and inflammatory diseases. By integrating advanced artificial intelligence, physics-based computational tools, and laboratory automation, DeepCure accelerates the identification and development of novel small molecules against historically intractable biological targets. The company's proprietary platform enables it to tackle targets that traditional drug discovery approaches have failed to drug, expanding the frontier of what is therapeutically achievable. DeepCure's pipeline reflects this ambition: its lead program, DC-9476, is a development candidate targeting multiple autoimmune diseases including rheumatoid arthritis, while DC-15442 is an oral STAT6 inhibitor demonstrating 100% in vivo inhibition of pSTAT6 and efficacy comparable to dupilumab across disease models. DeepCure also collaborates with world-class academic institutions, including the Leeds Institute of Rheumatic and Musculoskeletal Medicine, to advance its research. The company's approach combines computational intelligence with experimental validation, creating a tightly integrated loop that shortens timelines from target identification to clinical candidate nomination. DeepCure is primarily aimed at pharmaceutical partners, biotech investors, and research collaborators seeking next-generation AI-powered drug discovery capabilities.
Key Features
- AI-Driven Molecule Discovery: Uses advanced artificial intelligence to identify and design novel small molecule drug candidates against challenging biological targets.
- Physics-Based Computational Tools: Integrates physics-based modeling to predict molecular behavior, binding affinity, and in vivo efficacy with high accuracy.
- Laboratory Automation: Combines AI-driven design with automated laboratory workflows to accelerate experimental validation and iteration cycles.
- Intractable Target Drugging: Specializes in targeting historically undruggable proteins and pathways, expanding the therapeutic landscape for immune diseases.
- Clinical-Stage Pipeline: Has advanced multiple development candidates (DC-9476, DC-15442) into IND-enabling studies across autoimmune and inflammatory indications.
Use Cases
- Discovering novel oral small molecule drugs for autoimmune diseases like rheumatoid arthritis using AI-guided design.
- Targeting historically intractable proteins in immune pathways that have resisted conventional drug discovery approaches.
- Accelerating IND-enabling studies through integrated AI design and automated experimental validation pipelines.
- Developing orally bioavailable alternatives to injectable biologics such as dupilumab for inflammatory disease treatment.
- Forming research collaborations with academic institutions to advance mechanistic understanding of immune disease targets.
Pros
- Best-in-Class Efficacy Data: DC-15442 demonstrated 100% in vivo inhibition of pSTAT6 and efficacy comparable to the blockbuster biologic dupilumab, validating the platform's output quality.
- Integrated AI + Wet Lab Approach: The tight coupling of computational AI design with automated experimental validation creates a rapid, high-confidence drug discovery loop.
- Strong Academic Collaborations: Partnerships with leading institutions like the Leeds Institute of Rheumatic and Musculoskeletal Medicine bolster scientific credibility and access to expertise.
Cons
- Not a General-Purpose AI Tool: DeepCure is a therapeutics company, not a software platform — its AI capabilities are not accessible as a standalone product or API.
- Narrow Disease Focus: Current pipeline is concentrated in immune and inflammatory diseases, limiting near-term applicability to other therapeutic areas.
Frequently Asked Questions
What does DeepCure do?
DeepCure is an AI therapeutics company that uses advanced AI, physics-based tools, and laboratory automation to discover novel small molecule drugs, particularly for immune and inflammatory diseases.
What is DeepCure's lead drug candidate?
DeepCure has two key candidates: DC-9476, targeting multiple autoimmune diseases including rheumatoid arthritis, and DC-15442, an oral STAT6 inhibitor with 100% in vivo inhibition of pSTAT6 and efficacy comparable to dupilumab.
Where is DeepCure based?
DeepCure is headquartered in Boston, Massachusetts.
Who are DeepCure's collaborators?
DeepCure collaborates with world-class academic researchers, including those at the Leeds Institute of Rheumatic and Musculoskeletal Medicine.
What diseases does DeepCure focus on?
DeepCure focuses primarily on inflammatory and immune diseases, with programs in autoimmune conditions such as rheumatoid arthritis and indications driven by STAT6 signaling pathways.
